Selecting between ibrutinib, acalabrutinib and zanubrutinib in the frontline setting in CLL 

Farrukh Awan, MD, UT Southwestern Medical Center, Dallas, TX, comments on the choice between ibrutinib, acalabrutinib, and zanubrutinib for the first-line treatment of chronic lymphocytic leukemia (CLL). Dr Awan explains that ibrutinib is associated with a higher rate of cardiac side effects and therefore acalabrutinib and zanubrutinib would be the preferred options in this setting. In addition, Dr Awan notes that using time-limited approaches does not solve the problem of toxicity with BTK inhibitors as side effects usually arise early after treatment initiation. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.